Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AnGes to Acquire Exclusive Rights for CIN Therapeutic Vaccine for Cervical Precancerous Lesions in Major Countries
April 5, 2013
- MTPC Agrees to Transfer Tanabe Europe Shares to API in Tokyo
April 4, 2013
- Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
April 4, 2013
- Mochida Aims at Sales of 104 Billion Yen in FY2015
April 4, 2013
- Presidents of Pharmaceutical Companies Stress Globalization, Compliance in Welcoming Ceremonies for New Employees
April 4, 2013
- Nihon Chouzai to Make Choseido Subsidiary, to Sell Its Products Through Nihon Generic
April 4, 2013
- Plavix Rises to 3rd Place in Domestic Ethical Drug Market in 2012, Could Take No. 1 Spot This Year
April 4, 2013
- MSD Reports Downturn in Profits for 2012 Despite 2.7% Growth in Sales
April 3, 2013
- AZ K.K. Reports 5.1% Decline in 2012 Sales; Sales of Omepral and Casodex Down
April 3, 2013
- Bayer Yakuhin Reports Nearly 20% Drop in Operating Profit Despite Growth in Sales of Zetia
April 3, 2013
- Abbott Japan Names Mr Sakamoto as President, Mr Honda as Vice President
April 3, 2013
- Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
April 3, 2013
- Kaketsuken also Files NDA for Cell Culture-Based New Influenza Vaccine
April 3, 2013
- Taiho Assigns 54 Oncology MRs according to Cancer Type
April 3, 2013
- AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
April 2, 2013
- DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
April 2, 2013
- Gabriel Baertschi Takes Over as President of AZ K.K.
April 2, 2013
- MTPC Obtains Approval of SGLT-2 Inhibitor Canagliflozin in US
April 2, 2013
- 3 Companies’ Midterm Plans Foresee Poor Outlook for Domestic Market with “For-Reference-Only Figures,” “No Figures,” “Zero Growth”
April 2, 2013
- Mr Ninomiya Appointed as New President, Mr Mitani Exits to Become Advisor: Novartis Pharma
April 1, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…